rs7435196 — SLC2A9

SLC2A9 rs7435196 — An Intronic Variant in the Renal Urate Transporter Locus

Your kidneys play a central role in regulating uric acid levels, filtering and selectively reabsorbing urate through specialised transporters in the proximal tubule. The SLC2A9 gene encodes GLUT9¹¹ GLUT9
Glucose Transporter 9, a high-capacity voltage-driven urate transporter expressed in both the basolateral and apical membranes of the kidney proximal tubule; despite its name, GLUT9 transports urate far more efficiently than glucose. Variants in and around SLC2A9 consistently rank among the strongest genetic determinants of serum uric acid in genome-wide studies across multiple ancestries.

The rs7435196 variant is an intronic A>C change located at chromosome 4, position 9,965,932 (GRCh38), approximately 4.8 kilobases from the well-characterised SLC2A9 GWAS signal rs11942223. It lies deep within a large intron (c.681+14660 in coding notation) and does not alter the GLUT9 amino acid sequence. As of 2026, no genome-wide association studies or published clinical studies have reported a direct association between rs7435196 and uric acid levels, gout, or any other phenotype. The variant has zero citations in PubMed.

The Mechanism

rs7435196 is a non-coding intronic variant and does not directly change the GLUT9 protein. Its potential relevance derives from its position within the SLC2A9 locus — a region of the genome that harbours multiple independent signals for renal urate regulation. The SLC2A9 intronic region spanning positions 9.9–10.2 Mb on chromosome 4 contains regulatory elements, splice enhancers, and haplotype blocks that influence GLUT9 expression levels and transporter function. Non-coding variants in this region may alter transcription factor binding, affect mRNA splicing efficiency, or serve as proxies (via linkage disequilibrium) for causal regulatory variants nearby.

The proximity of rs7435196 to the established signal rs11942223 (~4.8 kb) raises the possibility that these variants partially tag the same regulatory haplotype block. However, this is not confirmed: the allele frequency distributions of the two variants differ substantially (rs11942223 shows T allele frequency ~74–78% in Europeans; rs7435196 shows A allele frequency ~57.6% in Europeans), suggesting they may not be in strong linkage disequilibrium and could represent distinct positions in the haplotype structure. Without published LD data specifically pairing rs7435196 with established SLC2A9 signals, whether this variant tags an independent or correlated effect cannot be determined.

The Evidence

There are no direct studies of rs7435196. What is known comes from the broader SLC2A9 literature:

Döring et al. (2008)²² Döring et al. (2008) conducted the landmark genome-wide association study that mapped the SLC2A9 intronic region as a major urate QTL, with variants in introns 4 and 6 explaining 1.2% of serum urate variance in men and up to 6% in women across German cohorts. The pronounced sex-specific effect was attributed to an interaction between SLC2A9 transporter regulation and estrogen's independent uricosuric action.

Vitart et al. (2008)³³ Vitart et al. (2008) independently replicated the SLC2A9 locus in Croatian and Scottish cohorts, establishing it as the strongest genetic region for serum uric acid in Europeans.

The allele frequency distribution of rs7435196 shows notable population heterogeneity: the C allele is common in African-ancestry populations (72%) but rare in East Asians (10.8%), while the A allele is more common in Europeans (57.6%). This pattern differs from the established risk signal at rs11942223 (where the T risk allele is uniformly common in Europeans, Africans, and South Asians at 74–78%, 55%, and 70% respectively), suggesting these variants may tag different underlying population history events rather than the same causal variant.

The evidence level for rs7435196 is emerging — the variant is in a gene with strong established relevance, but there are no direct association data for this specific rsid. Genotype-specific recommendations are based on the biological plausibility of the SLC2A9 locus, not proven effects of rs7435196 itself.

Practical Actions

Since the direct effect of rs7435196 on serum urate is uncharacterised, the practical guidance focuses on what is known to modulate urate levels through GLUT9-regulated renal excretion — the pathway where SLC2A9 variants exert their effect. The most impactful dietary interventions for urate management are: eliminating sugar-sweetened beverages (fructose both raises urate production and competes with urate for renal excretion), limiting purine-rich foods (organ meats, shellfish, beer), and increasing low-fat dairy intake (associated with modest urate reduction). These interventions apply regardless of SLC2A9 genotype but are most relevant when other SLC2A9 risk signals are present.

If you carry additional SLC2A9 risk variants (rs11942223 T allele or rs3733591 C allele) alongside this variant, the combined picture is more informative than any single variant alone.

Interactions

Within the SLC2A9 locus: rs7435196 is located 4.8 kb from rs11942223 and within the same broad intronic region as the established SLC2A9 urate signals. Without published LD data, whether these variants are correlated or independent is unknown. Carriers of risk alleles at the established signals (rs11942223 TT, rs3733591 CC) should weight those known-effect variants more heavily in assessing their SLC2A9 urate burden.

With ABCG2 rs2231142: ABCG2 regulates intestinal urate secretion through an entirely separate pathway from SLC2A9 renal reabsorption. These pathways are independent and additive: carrying risk alleles at both a renal reabsorption gene and an intestinal excretion gene produces higher serum urate than either alone.

Dietary fructose interaction: SLC2A9 intronic variants in this region have documented interactions with dietary fructose — the established signal at rs11942223 shows that C allele carriers lose their urate-clearance advantage under high fructose exposure. Whether rs7435196 participates in this interaction is unknown, but the proximity to rs11942223 makes it a reasonable precaution to limit sugar-sweetened beverages regardless of which specific SLC2A9 intronic variant is being examined.